We are an immuno-oncology company bringing breakthrough immunotherapies to patients with solid-tumor cancers.
Vicus’ lead drug product, VT-122, is the first multi-pathway neuro-immune modulator for the treatment of cancer. VT-122 is a chrono-formulation of etodolac and propranolol that inhibits beta adrenergic receptors 1-2, COX-2 enzyme & TRPA1 channel and the MAPK, PI3K, PKA, STAT3 & nociception signaling cascades. VT-122’s multi-pathway mode-of-action is designed to synergistically damp tumor-promoting inflammation, restore immune surveillance and improve treatment tolerance.
VT-122’s unique chrono-pharmacodynamic properties, along with the well-established safety profiles of its component drugs, maximize the potential to safely and significantly extend survival of patients with difficult to treat cancers.
VT-122 is currently in a Phase 2 clinical study of advanced liver cancer patients receiving sorafenib and in an Investigator-led Pilot study of metastatic pancreatic cancer patients receiving gemcitabine and nanoparticle albumin-bound-paclitaxel (GemNab).